Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Differences in the platelet mRNA landscape portend racial disparities in platelet function and suggest novel therapeutic targets
This study identifies gene expression differences at the population level that may affect platelet function and serve as potential biomarkers to identify CVD risk. Additionally, our analysis uncovers candidate novel druggable targets for future anti-platelet therapies.PMID:34255863 | DOI:10.1002/cpt.2363
Source: Clinical Pharmacology and Therapeutics - July 13, 2021 Category: Drugs & Pharmacology Authors: Kaitlin Garofano C Sehwan Park Cristina Alarcon Juan Avitia April Barbour David Diemert Claire M Fraser Paula N Friedman Anelia Horvath Kameron Rashid Mohammed Shaazuddin Alfateh Sidahmed Travis J O'Brien Minoli A Perera Norman H Lee Source Type: research

Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood, Craig R. Lee, Ian R. Mulrenin, Megan N. Gower, Joseph S. Rossi, Karen E. Weck, George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research

Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases
This study assessed the association between thromboembolic events (TEs) and immune-mediated diseases (IMDs) and characterized the risk profile of TEs among patients with IMDs.METHODS: An administrative claims database (2014-2018) was used to identify adults with ≥2 diagnoses on different dates for ≥1 IMD (IMD cohort; ankylosing spondylitis, atopic dermatitis, inflammatory bowel disease, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus); patients without an IMD diagnosis were assigned to the non-IMD cohort. Patients in the IMD cohort were matched 1:1 to patients ...
Source: Clinical Therapeutics - July 9, 2021 Category: Drugs & Pharmacology Authors: Juliana Setyawan Fan Mu Andres Yarur Miriam L Zichlin Hongbo Yang Catherine Fernan Emma Billmyer Nathaniel Downes Nassir Azimi Vibeke Strand Source Type: research

The Protective Effect of Liquiritin in Hypoxia/Reoxygenation-Induced Disruption on Blood Brain Barrier
Conclusions: Studies have shown that LQ can promote cell proliferation, migration as well as angiogenesis, and reduce cell apoptosis, which may be related to its inhibition of oxidative and ER stress, and then maintain the integrity of BBB. Given that five differential proteins were found by protein analysis, future studies will revolve around the five differential proteins.
Source: Frontiers in Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Source Type: research

Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases
Curr Pharm Des. 2021 Jul 1. doi: 10.2174/1381612827666210701154305. Online ahead of print.ABSTRACTA large percentage of people are being exposed to mortality due to cardiovascular diseases. Convention approaches have not provided satisfactory outcomes in the management of these diseases. To overcome the limitations of conventional approaches, nanomaterials like nanoparticles, nanotubes, micelles, lipid based nanocarriers, dendrimers, carbon based nano-formulations represent the new aspect of diagnosis and treatment of cardiovascular diseases. The unique inherent properties of the nanomaterials are the major reasons for the...
Source: Current Pharmaceutical Design - July 5, 2021 Category: Drugs & Pharmacology Authors: Rakesh K Sahoo Himani Singh Kamlesh Thakur Umesh Gupta Amit K Goyal Source Type: research

Antithrombotic effects of Huanglian Jiedu decoction in a rat model of ischaemia-reperfusion-induced cerebral stroke
CONCLUSION: Our results indicated that HLJDD regulated blood circulation by inhibiting platelet aggregation and thrombosis, which might also extensively contribute to the clinical prevention and treatment of cerebrovascular diseases.PMID:34196572 | DOI:10.1080/13880209.2021.1942505
Source: Pharmaceutical Biology - July 1, 2021 Category: Drugs & Pharmacology Authors: Huan Liu Xiaoyan Chen Yanling Liu Chunjuan Fang Shaofen Chen Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis
Conclusions: DOACs seem to be more efficacious in achieving LVT resolution compared with VKAs. However, there was no significant difference between the 2 groups in thromboembolic events, major bleeding, and all-cause mortality. Randomized controlled trials are needed to confirm our findings.
Source: American Journal of Therapeutics - July 1, 2021 Category: Drugs & Pharmacology Tags: Meta-analysis Source Type: research

Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Conclusions Overall, we found a moderate signal of higher frequency of reporting hemorrhage in rivaroxban compared with dabigatran and decreased hemorrhagic event reporting in apixaban compared with dabigatran. While this potential signal has not been confirmed in clinical trials or observational studies, in clinical practice, attention should be paid to the risk of potential hemorrhage when the patients switch from apixaban to dabigatran or rivaroxban.
Source: International Journal of Clinical Pharmacy - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Evaluation of Prescribing Practices and Outcomes Using Direct-Acting Oral Anticoagulants After Cardiac Surgery
Clin Ther. 2021 May 30:S0149-2918(21)00203-4. doi: 10.1016/j.clinthera.2021.04.009. Online ahead of print.ABSTRACTPURPOSE: Cardiac surgery patients frequently require anticoagulation. Warfarin remains the preferred agent, and a few trials have reported negative outcomes with the use of direct-acting oral anticoagulants (DOACs) in these patients. Therefore, limited literature exists that supports the dosing, safety, and efficacy of DOACs within the cardiac surgery population.METHODS: This single-center, retrospective analysis was conducted at a tertiary academic medical center. All data were extrapolated from electronic med...
Source: Clinical Therapeutics - June 3, 2021 Category: Drugs & Pharmacology Authors: Dareen M Kanaan Bryan M Cook Julie Kelly Rhynn Malloy Source Type: research

How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing
CONCLUSION: EHRA guide may not provide optimal remedial strategies. PK/PD modelling and simulation provide valid evidence on the remedial dosing regimen of rivaroxaban, which could help to minimise the risk of bleeding and thromboembolism.PMID:34058934 | DOI:10.1080/17512433.2021.1937126
Source: Pharmacological Reviews - June 1, 2021 Category: Drugs & Pharmacology Authors: Xiao-Qin Liu Yi-Wei Yin Chen-Yu Wang Zi-Ran Li Xiao Zhu Zheng Jiao Source Type: research